Re-purposed antiviral drugs without a purpose in COVID-19: a valuable lesson for clinicians
- 11 February 2021
- journal article
- editorial
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (9), 882-883
- https://doi.org/10.1093/eurheartj/ehab043
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Dexamethasone in Hospitalized Patients with Covid-19The New England Journal of Medicine, 2021
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial ResultsThe New England Journal of Medicine, 2021
- FDA Approval of Remdesivir - A Step in the Right DirectionThe New England Journal of Medicine, 2020
- Conflicting results on the efficacy of remdesivir in hospitalized Covid-19 patients: comment on the Adaptive Covid-19 Treatment TrialEuropean Heart Journal, 2020
- The widely promoted antimalarial drug hydroxychloroquine confers no mortality benefit in hospitalized patients with COVID-19: comment on the ‘Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19’European Heart Journal, 2020
- Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialThe Lancet, 2020
- Adaptive Designs for Clinical TrialsThe New England Journal of Medicine, 2016